Stock Market & Financial Investment News

News Breaks January 28, 2013 07:22 EDT JNJ, IDIX Medivir announces collaboration between Janssen, Idenix Medivir AB announced a non-exclusive collaboration between Janssen Pharmaceuticals (JNJ) and Idenix Pharmaceuticals (IDIX) for the clinical development of an all-oral direct-acting antiviral hepatitis C combination therapy. The collaboration will evaluate combinations including simeprevir, a once-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir, TMC647055, a potent once-daily NNI of the HCV polymerase, boosted with low dose ritonavir, being developed by Janssen and IDX719, Idenix’s once-daily pan-genotypic NS5A inhibitor. Clinical development plans include an initial drug-drug interaction study to begin in the first quarter of 2013, followed by phase II studies as agreed between the companies, and pending approval from regulatory authorities. The phase II program is expected to first evaluate the two-DAA combination of IDX719 and simeprevir plus ribavirin for 12 weeks in treatment-naïve HCV-infected patients. Subsequently, the companies plan to evaluate a three-DAA combination of IDX719, simeprevir, TMC647055/r, with or without ribavirin. The clinical trials will be conducted by Idenix. Both companies retain all rights to their respective compounds under this agreement. News For JNJ;IDIX From The Last 14 Days Check below for free stories on JNJ;IDIX the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 21, 2013 07:34 EDT IDIX UBS to host a conference Subscribe for More Information 07:24 EDT JNJ Global Health Care to host a conference Subscribe for More Information May 17, 2013 06:19 EDT JNJ J&J to end sales of of metal-on-metal hip replacements, Bloomberg reports Subscribe for More Information May 15, 2013 16:51 EDT JNJ FDA approves Simponi to treat ulcerative colitis Subscribe for More Information May 10, 2013 11:48 EDT JNJ Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 06:16 EDT JNJ Obesity surgery booming in India, Bloomberg reports Subscribe for More Information May 9, 2013 17:09 EDT JNJ Johnson & Johnson deal to settle sales practices probe stalls, WSJ reports Johnson & Johnson's $2.2B settlement with the Justice Department related to its promotion of certain drugs is on hold as the company is looking to avoid language in the agreement that could make it vulnerable to private lawsuits, reports The Wall Street Journal, citing people familiar with the talks. Reference Link 09:51 EDT JNJ J&J unit says first patient enrolled in reMARQable study Subscribe for More Information May 8, 2013 07:38 EDT JNJ BofA/Merrill's medical tech analyst hold an analyst/industry conference call Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.